TY - JOUR
T1 - Contemporary mortality risk prediction for percutaneous coronary intervention
T2 - Results from 588,398 procedures in the National Cardiovascular Data Registry
AU - Peterson, Eric D.
AU - Dai, David
AU - DeLong, Elizabeth R.
AU - Brennan, J. Matthew
AU - Singh, Mandeep
AU - Rao, Sunil V.
AU - Shaw, Richard E.
AU - Roe, Matthew T.
AU - Ho, Kalon K.L.
AU - Klein, Lloyd W.
AU - Krone, Ronald J.
AU - Weintraub, William S.
AU - Brindis, Ralph G.
AU - Rumsfeld, John S.
AU - Spertus, John A.
N1 - Funding Information:
Dr. Peterson has received research grants from Bristol-Myers Squibb , Merck Group , Sanofi-Aventis , St. Jude Medical, Inc. , American Heart Association , American College of Cardiology , and Society of Thoracic Surgeons ; and is a consultant for Kansas City Cardiomyopathy Questionnaire, Peripheral Artery Questionnaire, PRISM, and Seattle Angina Questionnaire. Bristol-Myers Squibb, Centocor, Eli Lilly & Company, and Pfizer. Dr. Rao has received research funding from Cordis Corporation (modest). Dr. Roe has received research grants from Bristol-Myers Squibb , Eli Lilly & Company , Portola Pharmaceutical , Sanofi-Aventis , and Schering-Plough Corporation ; and is a consultant for Adolor Corporation, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly & Company, Merck Group, Novartis Pharmaceutical Company, Sanofi-Aventis, and Schering-Plough Corporation. Dr. Ho serves on an independent clinical events committee for Harvard Clinical Research Institute, providing event adjudication services for Boston Scientific Corporation; and is a clinical advisor for Massachusetts Data Analysis Center under contract to the Department of Public Health for the Commonwealth of Massachusetts (an unpaid volunteer position). Dr. Rumsfeld is Chief Science Officer for the National Cardiovascular Data Registry. Dr. Spertus has a research contract from ACCF; grants from AHA , Amgen , Johnson & Johnson , and NIH ; grant support from Atherotech and Roche Diagnostics ; is a consultant for Novartis, United Healthcare, and St. Jude Medical; and holds copyrights/patents for Kansas City Cardiomyopathy Questionnaire, Peripheral Artery Questionnaire, PRISM, and Seattle Angina Questionnaire.
PY - 2010/5/4
Y1 - 2010/5/4
N2 - Objectives We sought to create contemporary models for predicting mortality risk following percutaneous coronary intervention (PCI). Background There is a need to identify PCI risk factors and accurately quantify procedural risks to facilitate comparative effectiveness research, provider comparisons, and informed patient decision making. Methods Data from 181,775 procedures performed from January 2004 to March 2006 were used to develop risk models based on pre-procedural and/or angiographic factors using logistic regression. These models were independently evaluated in 2 validation cohorts: contemporary (n = 121,183, January 2004 to March 2006) and prospective (n = 285,440, March 2006 to March 2007). Results Overall, PCI in-hospital mortality was 1.27%, ranging from 0.65% in elective PCI to 4.81% in ST-segment elevation myocardial infarction patients. Multiple pre-procedural clinical factors were significantly associated with inhospital mortality. Angiographic variables provided only modest incremental information to pre-procedural risk assessments. The overall National Cardiovascular Data Registry (NCDR) model, as well as a simplified NCDR risk score (based on 8 key pre-procedure factors), had excellent discrimination (c-index: 0.93 and 0.91, respectively). Discrimination and calibration of both risk tools were retained among specific patient subgroups, in the validation samples, and when used to estimate 30-day mortality rates among Medicare patients. Conclusions Risks for early mortality following PCI can be accurately predicted in contemporary practice. Incorporation of such risk tools should facilitate research, clinical decisions, and policy applications.
AB - Objectives We sought to create contemporary models for predicting mortality risk following percutaneous coronary intervention (PCI). Background There is a need to identify PCI risk factors and accurately quantify procedural risks to facilitate comparative effectiveness research, provider comparisons, and informed patient decision making. Methods Data from 181,775 procedures performed from January 2004 to March 2006 were used to develop risk models based on pre-procedural and/or angiographic factors using logistic regression. These models were independently evaluated in 2 validation cohorts: contemporary (n = 121,183, January 2004 to March 2006) and prospective (n = 285,440, March 2006 to March 2007). Results Overall, PCI in-hospital mortality was 1.27%, ranging from 0.65% in elective PCI to 4.81% in ST-segment elevation myocardial infarction patients. Multiple pre-procedural clinical factors were significantly associated with inhospital mortality. Angiographic variables provided only modest incremental information to pre-procedural risk assessments. The overall National Cardiovascular Data Registry (NCDR) model, as well as a simplified NCDR risk score (based on 8 key pre-procedure factors), had excellent discrimination (c-index: 0.93 and 0.91, respectively). Discrimination and calibration of both risk tools were retained among specific patient subgroups, in the validation samples, and when used to estimate 30-day mortality rates among Medicare patients. Conclusions Risks for early mortality following PCI can be accurately predicted in contemporary practice. Incorporation of such risk tools should facilitate research, clinical decisions, and policy applications.
KW - Outcomes
KW - Percutaneous coronary intervention
KW - Risk prediction
UR - http://www.scopus.com/inward/record.url?scp=77952294469&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952294469&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2010.02.005
DO - 10.1016/j.jacc.2010.02.005
M3 - Article
C2 - 20430263
AN - SCOPUS:77952294469
SN - 0735-1097
VL - 55
SP - 1923
EP - 1932
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 18
ER -